Nezam H Afdhal

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Hepatitis C pharmacogenetics: state of the art in 2010
    Nezam H Afdhal
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 53:336-45. 2011
  2. ncbi request reprint Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastroenterology 126:1302-11. 2004
  3. ncbi request reprint The natural history of hepatitis C
    Nezam H Afdhal
    Medical Director, Liver Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Semin Liver Dis 24:3-8. 2004
  4. pmc Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis
    Miroslaw Kornek
    Harvard Medical School, Boston, MA, USA
    Gastroenterology 143:448-58. 2012
  5. ncbi request reprint Use of growth factors with antiviral therapy for chronic hepatitis C
    Michael P Curry
    Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
    Clin Liver Dis 9:439-51, vii. 2005
  6. ncbi request reprint Duration of peginterferon therapy in acute hepatitis C: a randomized trial
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Hepatology 43:923-31. 2006
  7. pmc Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis
    Shaoyong Li
    Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 56:2094-105. 2012
  8. ncbi request reprint Role of epoetin alfa in maintaining ribavirin dose
    Nezam H Afdhal
    Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
    Gastroenterol Clin North Am 33:S25-35. 2004
  9. ncbi request reprint Antiviral therapy for treatment naïve patients with hepatitis C virus
    Sangik Oh
    Department of Medicine, Harvard Medical School, 25 Shattack Street, Boston, MA 02115, USA
    Gastroenterol Clin North Am 33:497-511, viii. 2004
  10. ncbi request reprint Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis
    Sanaa M Kamal
    Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Hepatology 43:771-9. 2006

Detail Information

Publications50

  1. doi request reprint Hepatitis C pharmacogenetics: state of the art in 2010
    Nezam H Afdhal
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 53:336-45. 2011
    ....
  2. ncbi request reprint Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastroenterology 126:1302-11. 2004
    ..This study assessed whether epoetin alfa could maintain RBV dose, improve quality of life (QOL), and increase hemoglobin (Hb) in anemic HCV-infected patients...
  3. ncbi request reprint The natural history of hepatitis C
    Nezam H Afdhal
    Medical Director, Liver Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Semin Liver Dis 24:3-8. 2004
    ..Progression of liver disease in 20 to 30% of patients can lead to compensated and eventually decompensated cirrhosis or hepatocellular carcinoma, or both. This article looks briefly at the epidemiology and natural history of hepatitis C...
  4. pmc Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis
    Miroslaw Kornek
    Harvard Medical School, Boston, MA, USA
    Gastroenterology 143:448-58. 2012
    ..Patients with nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) can be differentiated from those with CHC based on activation of distinct sets of immune cells in the liver...
  5. ncbi request reprint Use of growth factors with antiviral therapy for chronic hepatitis C
    Michael P Curry
    Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
    Clin Liver Dis 9:439-51, vii. 2005
    ....
  6. ncbi request reprint Duration of peginterferon therapy in acute hepatitis C: a randomized trial
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Hepatology 43:923-31. 2006
    ..Duration of treatment should be further optimized based on genotype and rapid virologic response at week 4...
  7. pmc Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis
    Shaoyong Li
    Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 56:2094-105. 2012
    ..46, P = 0.05). In addition, supernatants from HCV-stimulated IHL of slow progressors specifically increased fibrolytic gene expression in HSC and treatment with anti-TGFβ mAb abrogated such expression...
  8. ncbi request reprint Role of epoetin alfa in maintaining ribavirin dose
    Nezam H Afdhal
    Department of Medicine, Liver Center, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
    Gastroenterol Clin North Am 33:S25-35. 2004
    ....
  9. ncbi request reprint Antiviral therapy for treatment naïve patients with hepatitis C virus
    Sangik Oh
    Department of Medicine, Harvard Medical School, 25 Shattack Street, Boston, MA 02115, USA
    Gastroenterol Clin North Am 33:497-511, viii. 2004
    ..Recent data suggest that an SVR can be equated with a biochemical, virological,and histological response that is sustained for up to 5 years and is conceptually a cure of HCV in 90% of patients...
  10. ncbi request reprint Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis
    Sanaa M Kamal
    Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Hepatology 43:771-9. 2006
    ..In conclusion, serial cytokine and fibrosis markers can accurately determine the rate at which fibrosis is progressing, identifying both those with rapid fibrosis and those with stable disease...
  11. ncbi request reprint Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States
    Laren Becker
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 7:696-701. 2009
    ..Hepascore uses noninvasive serum markers and has been validated in Australian and European populations for predicting different degrees of fibrosis. This study validated this test in a U.S. population...
  12. ncbi request reprint Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 46:324-9. 2007
    ..Longer studies to assess potential effects of IDN-6556 on liver inflammation and fibrosis are merited...
  13. ncbi request reprint Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index
    Thomas B Kelleher
    Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
    J Hepatol 43:78-84. 2005
    ..To examine if serum fibrosis biomarkers could accurately identify the stage of liver disease amongst hepatitis C (HCV) and HIV co-infected patients...
  14. doi request reprint Diagnosis and quantitation of fibrosis
    Diarmuid S Manning
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, and Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 134:1670-81. 2008
    ..This article reviews the current role of liver biopsy in the assessment of hepatic fibrosis and discusses the role of the newer noninvasive methods including serum markers and radiologic tests...
  15. ncbi request reprint Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice
    Helen H Wang
    Department of Medicine, Liver Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard Digestive Diseases Center, Boston, MA, USA
    J Lipid Res 47:778-86. 2006
    ..These studies provide insights into therapeutic approaches to cholesterol gallstones in high-risk subjects, especially those exposed to high levels of estrogen...
  16. doi request reprint Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    JAMA 308:608-16. 2012
    ..Improved noninvasive diagnostic tests, a clearer understanding of the natural history of NAFLD, and large, well-designed clinical trials are needed...
  17. doi request reprint Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition
    Valerie Byrnes
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Hepatol 56:549-56. 2012
    ..We aimed to evaluate the effect of pegylated interferon/ribavirin (PIFN/R) and HCV clearance on cerebral metabolism, and neuropsychological performance...
  18. doi request reprint Therapeutic strategies for chronic hepatitis B virus infection in 2008
    Asim Khokhar
    Liver Research Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Med 121:S33-44. 2008
    ..Long-term studies indicate that effective suppression of viral replication improves clinical outcome, with improvement of liver histology and, it is assumed, a decreased risk for development of hepatocellular carcinoma...
  19. doi request reprint Lith genes and genetic analysis of cholesterol gallstone formation
    Helen H Wang
    Liver Center and Gastroenterology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Gastroenterol Clin North Am 39:185-207, vii-viii. 2010
    ....
  20. doi request reprint Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts Electronic address
    Gastroenterology 146:442-452.e1. 2014
    ....
  21. ncbi request reprint Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice
    Helen H Wang
    Department of Medicine, Liver Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard Digestive Diseases Center, Boston, Massachusetts 02215, USA
    Gastroenterology 131:210-22. 2006
    ..The gel-forming mucins play an important role in the early stage of cholesterol gallstone formation. We investigated whether the gallbladder epithelial mucin encoded by mucin gene 1 (MUC1) influences susceptibility to gallstones...
  22. ncbi request reprint Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response
    Sanaa M Kamal
    Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Gastroenterology 130:632-8. 2006
    ..Pegylated interferon therapy has not been adequately evaluated in acute hepatitis C virus (HCV) infection. This randomized trial assessed the efficacy, safety, and timing of pegylated interferon alfa-2b for treatment of acute hepatitis C...
  23. doi request reprint Ultrasound-based hepatic elastography: origins, limitations, and applications
    Eric B Cohen
    Yale University School of Medicine, Department of Digestive Diseases, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Gastroenterol 44:637-45. 2010
    ..HE is now being used in lieu of liver biopsy to investigate the natural history of chronic liver diseases. Additional studies are required to better define the appropriate role of HE in clinical practice...
  24. pmc Liver cirrhosis
    Detlef Schuppan
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 371:838-51. 2008
    ..This Seminar focuses on the diagnosis, complications, and management of cirrhosis, and new clinical and scientific developments...
  25. ncbi request reprint The clinical significance of persistently normal ALT in chronic hepatitis B infection
    Michelle Lai
    Beth Israel Deaconess Medical Center, Division of Hepatology, Harvard Medical School, Boston, MA, USA
    J Hepatol 47:760-7. 2007
    ..The role of ALT levels as a predictor of liver injury has recently been questioned. The aim of the study was to determine whether normal ALT is associated with liver injury in a cohort of HBV patients undergoing liver biopsy...
  26. doi request reprint The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis
    Detlef Schuppan
    Beth Israel Deaconess Medical Center, Division of Gastroenterology, Harvard Medical School, Boston, MA 02215, USA
    Liver Int 30:795-808. 2010
    ..Combined with a better understanding of the pathophysiological processes that underlie the mechanisms of hepatic fibrogenesis in NASH, rapid clinical validation of novel therapies is expected...
  27. ncbi request reprint The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver
    Valerie Byrnes
    Department of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Gastroenterol 102:1654-9. 2007
    ..To evaluate the outcome of arterially enhancing nodules (AENs) measuring <20 mm detected on MRI in patients with cirrhosis...
  28. pmc Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells
    Miroslaw Kornek
    Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 53:230-42. 2011
    ..Mass spectrometry, fluorescence-activated cell sorting analysis, and function blocking antibodies revealed CD147/Emmprin as a candidate transmembrane molecule in HSC fibrolytic activation by CD8+ T cell MPs...
  29. ncbi request reprint Evaluation of liver fibrosis: a concise review
    Nezam H Afdhal
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02125, USA
    Am J Gastroenterol 99:1160-74. 2004
    ..The limitations of utilization of these markers for both cross-sectional diagnosis of fibrosis and monitoring disease progression or regression are discussed...
  30. doi request reprint Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease
    Noah T Zinkin
    Liver Center, Department of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 14:470-7. 2008
    ....
  31. doi request reprint Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia
    Nezam H Afdhal
    Division of Gastroenterology Liver Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 367:716-24. 2012
    ....
  32. ncbi request reprint Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosis
    Andres Cardenas
    Liver Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Scand J Gastroenterol 43:328-33. 2008
    ..The aim of this study was to determine the effects of SP (dose--13 pg/kg) and its specific inhibitor, RP67580 (dose--300 microg/kg) on mean arterial pressure (MAP) and portal pressure (PP) in cirrhotic rats and controls...
  33. ncbi request reprint Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol gallstones
    Helen H Wang
    Department of Medicine, Liver Center and Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard Digestive Diseases Center, Boston, Massachusetts 02215, USA
    Gastroenterology 127:239-49. 2004
    ..It is hypothesized that estrogen enhances cholesterol cholelithogenesis by augmenting functions of hepatic estrogen receptors (ERs)...
  34. doi request reprint Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade
    Michelle Lai
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Gastroenterol 106:2121-2. 2011
    ..Am J Gastroenterol 2011; 106:2121-2122; doi:10.1038/ajg.2011.343...
  35. ncbi request reprint Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes
    David Q H Wang
    Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, DA 601, Boston, MA 02215, USA
    Curr Gastroenterol Rep 6:140-50. 2004
    ..Because exceptionally close homology exists between mouse and human genomes, the orthologous human LITH genes can often be recognized after mouse genes are identified...
  36. ncbi request reprint Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 21:2209-16. 2007
    ....
  37. ncbi request reprint Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
    Paul J Pockros
    Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 40:1450-8. 2004
    ..Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy...
  38. ncbi request reprint Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis
    Zachary D Goodman
    Armed Forces Institute of Pathology, Division of Hepatic Pathology, Veterans Administration Special Reference Laboratory for Pathology, Washington, DC, USA
    Hepatology 45:886-94. 2007
    ....
  39. ncbi request reprint Management of hepatitis C virus in special populations: patient and treatment considerations
    Robert G Gish
    Liver Transplant Program and Division of Hepatology and Complex GI, California Pacific Medical Center, 2340 Clay Street 232, San Francisco, CA 94115, USA
    Clin Gastroenterol Hepatol 3:311-8. 2005
    ..Close monitoring and management of therapeutic side effects are required to assist these patients in adhering to therapy...
  40. ncbi request reprint Iron, HCV, and liver cancer: hard metal setting the pace?
    Sebastian Mueller
    Gastroenterology 130:2229-34. 2006
  41. ncbi request reprint Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
    John G McHutchison
    ALT Alliance for Liver Therapy Group, Division of Gastroenterology and Hepatology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Hepatology 46:1341-9. 2007
    ..The data support further clinical studies of CPG 10101 for treating chronic HCV infection...
  42. ncbi request reprint Race, insulin resistance and hepatic steatosis in chronic hepatitis C
    Hari S Conjeevaram
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:80-7. 2007
    ..32-0.91, P = 0.02). Insulin resistance but not steatosis was associated with a lower rate of sustained virological response when adjusted for known factors that predict response (relative risk 0.87, 95% CI 0.77-0.99, P = 0.028)...
  43. doi request reprint Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C
    Keyur Patel
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Gastroenterol Hepatol 6:242-7. 2008
    ..We hypothesized that a noninvasive test of liver fibrosis can accurately stage liver fibrosis. We prospectively evaluated the FIBROSpect II (FSII) biomarker panel versus pathology assessment and a quantitative measure of fibrosis...
  44. ncbi request reprint Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
    John G McHutchison
    Duke University and Duke Clinical Research Institute, Durham, NC 27705, USA
    N Engl J Med 357:2227-36. 2007
    ..We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis...
  45. ncbi request reprint Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C
    Gamal Esmat
    National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
    J Hepatol 46:620-7. 2007
    ..We evaluated whether surrogate serum biomarkers for liver injury are comparable to liver biopsy in Egyptian patients with hepatitis C virus (HCV) infection...
  46. ncbi request reprint Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis
    Nezam H Afdhal
    J Hepatol 46:543-5. 2007
  47. ncbi request reprint The not so good effects of nitric oxide inhibition with methylene blue in cirrhosis and ascites
    Andres Cardenas
    Dig Dis Sci 52:939-40. 2007
  48. ncbi request reprint Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis?
    Nezam H Afdhal
    Clin Chem 50:1299-300. 2004
  49. ncbi request reprint Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus
    Mark S Sulkowski
    Division of Infectious Diseases Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 19:585-92. 2005
    ....
  50. ncbi request reprint Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests?
    Nezam H Afdhal
    Hepatology 37:972-4. 2003